A1 Journal article (refereed)
Heme Oxygenase-1 and Blood Bilirubin Are Gradually Activated by Oral D-Glyceric Acid (2022)


Hirvonen, O. P., Lehti, M., Kyröläinen, H., & Kainulainen, H. (2022). Heme Oxygenase-1 and Blood Bilirubin Are Gradually Activated by Oral D-Glyceric Acid. Antioxidants, 11(12), Article 2319. https://doi.org/10.3390/antiox11122319


JYU authors or editors


Publication details

All authors or editorsHirvonen, O. Petteri; Lehti, Maarit; Kyröläinen, Heikki; Kainulainen, Heikki

Journal or seriesAntioxidants

eISSN2076-3921

Publication year2022

Publication date23/11/2022

Volume11

Issue number12

Article number2319

PublisherMDPI

Publication countrySwitzerland

Publication languageEnglish

DOIhttps://doi.org/10.3390/antiox11122319

Publication open accessOpenly available

Publication channel open accessOpen Access channel

Publication is parallel published (JYX)https://jyx.jyu.fi/handle/123456789/84095


Abstract

It has been shown that small doses of oral D-glyceric acid (DGA) activate mitochondrial metabolism and reduce inflammation among 50–60-year-old healthy volunteers. The present results with the same small doses reveal that after a 4-day DGA regimen, a dose of DGA activated the HO-1 pathway acutely, while enhanced inflammatory status after the 4-day DGA regimen seemed to be able to downregulate the HO-1 pathway in non-acute measurement. Blood bilirubin was strongly upregulated towards the end of the altogether 21-day study period with positive associations towards improved inflammation and reduced blood triglycerides. After the 4-day DGA regimen, hepatic inflow of blood bilirubin with albumin as the carrier was clearly upregulated in the lower-aerobic-capacity persons. At the same time also, blood triglycerides were down, pointing possibly to the activation of liver fatty acid oxidation. The combination of activated aerobic energy metabolism with transient HO-1 pathway activation and the upregulation of blood bilirubin may reduce the risks of chronic diseases, especially in aging. Furthermore, there exist certain diseases with unsatisfactorily-met medical needs, such as fatty and cholestatic liver diseases, and Parkinson’s disease, that can be possibly ameliorated with the whole-body mechanism of the action of the DGA regimen.


Keywordsmitochondriametabolisminflammationtriglyceridesdiseasesliver diseasesParkinson's diseaseblood

Free keywordsHO-1; bilirubin; HIF-1α; subclinical inflammation; ROS


Contributing organizations


Ministry reportingYes

Reporting Year2022

JUFO rating1


Last updated on 2024-22-04 at 15:19